

Please try another search
(Reuters) -AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine.
"Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data," a spokesperson for the company said in a statement.
Oxford did not immediately respond to a request for comment outside business hours.
The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford.
"Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised," Douglas told FT.
A lab-study last week found that AstraZeneca (NASDAQ:AZN)'s antibody cocktail Evusheld retained neutralising activity against the Omicron variant.
Vaccine makers Pfizer/BioNTech and Moderna (NASDAQ:MRNA) also previously said they were working on Omicron- specific COVID-19 vaccines. Moderna said hopes to start clinical trials early next year.
(Reuters) - Rivian Automotive said on Friday Charly Mwangi, who helped kick-start the electric-vehicle maker's manufacturing process, will leave the company. Mwangi, a former...
LONDON (Reuters) - Low-cost carrier easyJet (LON:EZJ) is to cancel more than 200 flights over the next 10 days due to airport delays and other restrictions, disrupting travel...
SHANGHAI (Reuters) - China's first public real estate investment trusts (REITs) based on residential properties will be launched soon, as regulators step up efforts to channel...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.